Greenwich LifeSciences (GLSI) said Thursday that it has initiated new clinical sites in the US for a phase 3 trial of GLS-100, a fast-track-designated immunotherapy to prevent breast cancer recurrences.
The clinical trial has recently been activated at City of Hope network sites in southern California, Arizona, Atlanta, and Illinois.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.